Skip to main content

Advertisement

SpringerLink
Log in

Chromoendoscopy for Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Disease

  • Large Intestine (B Cash, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Chromoendoscopy utilizes colorimetric techniques to increase detection of lesions that are difficult to see or cannot be seen with conventional white light endoscopy. Multiple studies have demonstrated that chromoendoscopy with dye spraying significantly increases the detection of dysplastic lesions in patients with chronic inflammatory bowel disease (IBD) of the colon undergoing colonoscopy. Furthermore, chromoendoscopy may obviate the need for random biopsies and pending additional studies and may allow increased intervals between surveillance exams, reducing costs while increasing the sensitivity for detection of dysplasia per exam. Despite convincing data supporting the use of chromoendoscopy for IBD colonic surveillance, it is seldom utilized outside of academic centers. Here, we review the current approach to colorectal cancer surveillance in IBD focusing on the data supporting the use of chromoendoscopy including its use in a community setting and offer practical recommendations for incorporating chromoendoscopy as a routine part of surveillance in IBD regardless of practice setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer: a population-based study. NEJM. 1990;323:1228–33. extent of colitis, time since diagnosis and risk of CRC.

    Article  PubMed  CAS  Google Scholar 

  2. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in chronic ulcerative colitis: a meta-analysis. Gut. 2001;48:526–35. Meta analysis suggesting high risk of CRC in chronic IBD.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Eaden JA, Mayberry JF. Colorectal cancer complicating ulcerative colitis: a review. Am J Gastroenterol. 2000;95(10):2710–9.

    Article  PubMed  CAS  Google Scholar 

  4. Gillen CD, Walmsley RS, Prior P, et al. Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis. Gut. 1994;35(11):1590–2. UC CD risk same.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91(4):854–62. UC CD risk similar.

    Article  PubMed  CAS  Google Scholar 

  6. Eaden JA, Ward BA, Mayberry JF. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc. 2000;51(2):123–8.

    Article  PubMed  CAS  Google Scholar 

  7. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol (2009) advance online publication, 6 January doi: 10.1038/ajg.2008.168 (ACG practice guidelines in CD)

  8. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–23. ACG Practice Guidelines in UC.

    Article  PubMed  Google Scholar 

  9. Leighton JA, Shen B, Baron TH, Adler DG, Davila R, Egan JV, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc. 2006;63(4):558–65. ASGE endoscopy guidelines in IBD.

    Article  PubMed  Google Scholar 

  10. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):746–74. Outlines US practice guidelines on CRC surveillance in IBD.

    Article  PubMed  Google Scholar 

  11. Rutter MD et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  12. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099–105.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Rubin DT, Dezheng H, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case control study. CGH. 2013;11:1601–8. Confirms histologic inflammation as a risk factor for CRC in IBD, CRC risk higher in males and that thiopurine use protective against CRC.

    Google Scholar 

  14. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011;140(6):1807–16. Review of inflammation and CRC in IBD.

    Article  PubMed  CAS  Google Scholar 

  15. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56:48–54.

    Article  PubMed  Google Scholar 

  16. Jess T, Rungoe C, Peyrin–Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10(6):639–45. Meta-analysis of population based studies of CRC in UC showing much lower risk compared to older studies from tertiary referral centers.

    Article  PubMed  Google Scholar 

  17. Winther KV, Jess T, Langholz E, et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol. 2004;2:1088–95.

    Article  PubMed  Google Scholar 

  18. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130:1030–8. lower risk.

    Article  PubMed  Google Scholar 

  19. Jess T, Simonsen J, Jorgensen KT, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143:375–81. population based study showing lower risk of CRC.

    Article  PubMed  Google Scholar 

  20. Herrinton LJ, Liu L, Levin TR, et al. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 2012;143:382–9. decreasing incidence and mortality of CRC in IBD over time.

    Article  PubMed  Google Scholar 

  21. Lutgens MW et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013;19(4):789–99. Meta-analysis of population based cohort studies of CRC risk in IBD.

    Article  PubMed  Google Scholar 

  22. Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastro and Hep. 2014;12:265–27. USA population based study showing lower CRC risk than previously reported.

    Article  Google Scholar 

  23. Rubin DT, LoSavio A, Yadron N, et al. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:1346–50.

    Article  PubMed  CAS  Google Scholar 

  24. Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylates is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol. 2011;106(4):731–6.

    Article  PubMed  CAS  Google Scholar 

  25. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta analysis of observational studies. Am J Gastroenterol. 2005;100:1345–53. doi: 10.1111/j.1572-0241.2005.41442.

    Article  PubMed  CAS  Google Scholar 

  26. van Schaik FD, van Oijen MG, Smeets HM, et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut. 2012;61(2):235–40.

    Article  PubMed  Google Scholar 

  27. Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn’s disease or adenomas. (2011). National Institute for Health and Clinical Excellence: Guidance. London.

  28. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5):666–89. British GI society guidelines endorsing Chromoendoscopy for IBD surveillance exams.

    Article  PubMed  Google Scholar 

  29. Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7(12):982–1018. ECCO guidelines endorsing chromoendoscopy in IBD surveillance.

    Article  PubMed  Google Scholar 

  30. Kaminski MF, Hassan C, Bisschops R, Pohl J, Pellise M, Dekker E, et al. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2014;46(5):435–57. ESGE review of advanced imaging for dysplasia/cancer detection in a variety of setting including IBD surveillance for which chromoendoscopy strongly endorsed.

    Article  PubMed  Google Scholar 

  31. Choi PM, Nugent FW, Schoetz Jr DJ, et al. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology. 1993;105(2):418–24.

    PubMed  CAS  Google Scholar 

  32. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology. 1994;107(4):934–44.

    PubMed  CAS  Google Scholar 

  33. Karlén P, Kornfeld D, Broström O, et al. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut. 1998;42(5):711–4.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Lutgens MW et al. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br J Cancer. 2009;101:1671–5.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  35. Provenzale D, Kowdley KV, Arora S, Wong JB. Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. Gastroenterology. 1995;109(4):1188–96. cost effective modeling with conventional colonoscopy, NNT = 14.

    Article  PubMed  CAS  Google Scholar 

  36. Rubin PH, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology. 1999;117:1295–300. Polypectomy for polyps followed by surveillance effective in IBD.

    Article  PubMed  CAS  Google Scholar 

  37. Odze RD, Farraye FA, Hecht JL, Hornick J. Long term outcome confirms that polypectomy is adequate treatment for adenoma-like DALMS in ulcerative colitis. Clin Gastro Hepatol. 2004;2:534–41. Polypectomy for polyps followed by surveillance effective in IBD.

    Article  Google Scholar 

  38. Wanders LK, Dekker E, Pullens B, Bassett P, Travis SP, East JE. Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol (2013).

  39. Rubin CE, Haggitt RC, Burmer GC, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology. 1992;103:1611–20.

    PubMed  CAS  Google Scholar 

  40. Bernstein CN. How do we assess the value of surveillance techniques in ulcerative colitis. J Gastrointest Surg. 1998;2(4):318–21.

    Article  PubMed  CAS  Google Scholar 

  41. van Rijn AF, Fockens P, Siersema PD, Oldenburg B. Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn’s colitis patients in the Netherlands. World J Gastroenterol. 2009;15(2):226–30.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Rodriguez SA, Collins JM, Knigge KL, Eisen GM. Surveillance and management of dysplasia in ulcerative colitis. Gastrointest Endosc. 2007;65(3):432–9.

    Article  PubMed  Google Scholar 

  43. van den Broek FJ, Stokkers PC, Reitsma JB, Boltjes RP, Ponsioen CY, Fockens P, et al. Random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis: low yield and absence of clinical consequences. Am J Gastroenterol. (2011). Very low yield of random biopsies.

  44. Rutter MD. Surveillance programmes for neoplasia in colitis. J Gastroenterol. 2011;46 Suppl 1:1–5. Very low yield of random biopsies.

    Article  PubMed  Google Scholar 

  45. Rubin DT, Rothe JA, Hetzel JT, Cohen RD, Hanauer SB. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007;65(7):998–1004.

    Article  PubMed  Google Scholar 

  46. Rutter MD, Saunders BP, Wilkinson KH, Kamm MA, Williams CB, Forbes A. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc. 2004;60(3):334–9.

    Article  PubMed  Google Scholar 

  47. Murthy SK, Kiesslich R. Evolving endoscopic strategies for detection and treatment of neoplastic lesions in inflammatory bowel disease. Gastrointest Endosc. 2013;77(3):351–9. Excellent overview of evolving endoscopic approach to surveillance in IBD.

    Article  PubMed  Google Scholar 

  48. Kiesslich R, Neurath MF. Chromoendoscopy in inflammatory bowel disease. Gastroenterol Clin N Am. 2012;41.2:291–302. Concise review of Chromoendoscopy in UC.

    Article  Google Scholar 

  49. Ridell RH et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983;14:931–68.

    Article  Google Scholar 

  50. Rutter MD, Riddell RH. Colorectal dysplasia in inflammatory bowel disease: a clinicopathologic perspective. Clin Gastroenterol Hepatol. 2013. Review of dysplasia in IBD.

  51. Maser EA, Sachar DB, Kruse D, et al. High rates of metachronous colon cancer or dysplasia after segmental resection or subtotal colectomy in Crohn’s colitis. Inflamm Bowel Dis. 2013;19:1827–32.

    PubMed  Google Scholar 

  52. Hurlstone DP, Sanders DS, Atkinson R, Hunter MD, McAlindon ME, Lobo AJ, et al. Endoscopic mucosal resection for flat neoplasia in chronic ulcerative colitis: can we change the endoscopic management paradigm? Gut. 2007;56(6):838–46.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Smith LA, Baraza W, Tiffin N, Cross SS, Hurlstone DP. Endoscopic resection of adenoma-like mass in chronic ulcerative colitis using a combined endoscopic mucosal resection and cap assisted submucosal dissection technique. Inflamm Bowel Dis. 2008;14(10):1380–6.

    Article  PubMed  Google Scholar 

  54. Blonski W, Kundu R, Furth EF, Lewis J, Aberra F, Lichtenstein GR. High-grade dysplastic adenoma-like mass lesions are not an indication for colectomy in patients with ulcerative colitis. Scand J Gastroenterol. 2008;43(7):817–20.

    Article  PubMed  Google Scholar 

  55. Moss A, Bourke MJ, Williams SJ, Hourigan LF, Brown G, Tam W, et al. Endoscopic mucosal resection outcomes and prediction of submucosal cancer from advanced colonic mucosal neoplasia. Gastroenterology. 2011;140(7):1909–18.

    Article  PubMed  Google Scholar 

  56. van Schaik FD, ten Kate FJ, Offerhaus GJ, Schipper ME, Vleggaar FP, van der Woude CJ, et al. Misclassification of dysplasia in patients with inflammatory bowel disease: consequences for progression rates to advanced neoplasia. Inflamm Bowel Dis. 2011;17(5):1108–16.

    Article  PubMed  Google Scholar 

  57. Navaneethan U, Jegadeesan R, Gutierrez NG, Venkatesh PG, Hammel JP, Shen B, et al. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance. J Crohns Colitis. 2013;7(12):e684–91.

    Article  PubMed  Google Scholar 

  58. Pekow JR, Hetzel JT, Rothe JA, Hanauer SB, Turner JR, Hart J, et al. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010;16(8):1352–6.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Zisman TL, Bronner MP, Rulyak S, Kowdley KV, Saunders M, Lee SD, et al. Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines. Inflamm Bowel Dis. 2012;18(12):2240–6.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Thomas T, Abrams KA, Robinson RJ, Mayberry JF. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther. 2007;25(6):657–68.

    Article  PubMed  CAS  Google Scholar 

  61. Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003;125(5):1311–9.

    Article  PubMed  Google Scholar 

  62. Blackstone MO, Riddell RH, Rogers BH, et al. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology. 1981;80(2):366–74. Initial description of DALM lesion.

    PubMed  CAS  Google Scholar 

  63. Mescoli C, Albertoni L, D’incá R, Rugge M. Dysplasia in inflammatory bowel diseases. Dig Liver Dis. 2012. doi:10.1016/j.dld.2012.07.013.

    PubMed  Google Scholar 

  64. East JE. Colonoscopic cancer surveillance in inflammatory bowel disease: what’s new beyond random biopsy? Clin Endosc. 2012;45:274–7. Concise review of evolution from random biopsies to Chromoendoscopy.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Devuni D, Vaziri H, Anderson JC. Chromocolonoscopy. Gastroenterol Clin N Am. 2013;42:521–45. doi:10.1016/j.gtc.2013.05.002. Comprehensive review of chromoendoscopy.

    Article  Google Scholar 

  66. Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003;124:880–8. First published trial of Chromoendoscopy in IBD surveillance.

    Article  PubMed  Google Scholar 

  67. Rutter MD, Saunders BP, Schofield G, et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut. 2004;53:256–60.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  68. Hurlstone DP, Sanders DS, Lobo AJ, McAlindon ME, Cross SS. Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy. 2005;37:1186–92.

    Article  PubMed  CAS  Google Scholar 

  69. Marion JF, Waye JD, Present DH, et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol. 2008;103:2342–9.

    Article  PubMed  Google Scholar 

  70. Matsumoto T, Nakamura S, Jo Y, Yao T, Iida M. Chromoscopy might improve diagnostic accuracy in cancer surveillance for ulcerative colitis. Am J Gastroenterol. 2003;98:1827–33.

    Article  PubMed  Google Scholar 

  71. Hlavaty T, Huorka M, Koller T, Zita P, Kresanova E, Rychly B, et al. Colorectal cancer screening in patients with ulcerative and Crohn’s colitis with use of colonoscopy, chromoendoscopy and confocal endomicroscopy. Eur J Gastroenterol Hepatol. 2011;23(8):680–9.

    Article  PubMed  Google Scholar 

  72. Gunther U, Kusch D, Heller F, Burgel N, Leonhardt S, Daum S, et al. Surveillance colonoscopy in patients with inflammatory bowel disease: comparison of random biopsy vs. targeted biopsy protocols. Int J Colorectal Dis. 2011;26(5):667–72.

    Article  PubMed  Google Scholar 

  73. N Jasutkar, S Reinert, M Resnick, SA Shah (2012) Chromoendoscopy in community GI: a single physician experience. Poster presentation. IBD Advances, Hollywood, FL

  74. Wu L, Li P, Wu J, et al. The diagnostic accuracy of chromoendoscopy for dysplasia in ulcerative colitis: meta-analysis of six randomized controlled trials. Colorectal Dis. 2012;14:416–20. Meta-analysis showing efficacy of Chromoendoscopy in UC surveillance.

    Article  PubMed  CAS  Google Scholar 

  75. Subramanian V, Mannath J, Ragunath K, Hawkey CJ. Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33(3):304–12. Meta-analysis showing efficacy of Chromoendoscopy in IBD surveillance.

    Article  PubMed  CAS  Google Scholar 

  76. Dekker E, van den Broek FJ, Reitsma JB, et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy. 2007;39:216–21.

    Article  PubMed  CAS  Google Scholar 

  77. van den Broek FJ, Fockens P, van Eeden S, et al. Narrow-band imaging versus high-definition endoscopy for the diagnosis of neoplasia in ulcerative colitis. Endoscopy. 2011;43:108–15.

    Article  PubMed  Google Scholar 

  78. Ignjatovic A, East JE, Subramanian V, et al. Narrow band imaging for detection of dysplasia in colitis: a randomized controlled trial. Am J Gastroenterol Gastroenterol. 2012. doi:10.1038/ajg.2012.67.

    Google Scholar 

  79. Soetikno R, Subramanian V, Kaltenbach T, Rouse RV, Sanduleanu S, Suzuki N, et al. The detection of nonpolypoid (flat and depressed) colorectal neoplasms in patients with inflammatory bowel disease. Gastroenterology. 2013;144(7):1349–52. Concise review of chromoendoscopy with practical information on incorporating into practice with link to video.

    Article  PubMed  Google Scholar 

  80. Konijeti GG, et al. Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients with ulcerative colitis. Gastrointest Endosc. (2013) Nov 18. [Epub ahead of print]

  81. Farraye FA, Schroy P. Chromoendoscopy: a new vision for colonoscopic surveillance in IBD. Gastroenterology. 2006;131:323–5. which Dye.

    Article  PubMed  Google Scholar 

  82. Kiesslich R, Neurath MF. Surveillance colonoscopy in ulcerative colitis: magnifying chromoendoscopy in the spotlight. Gut. 2004;53(2):165–7. Pit pattern classification.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  83. Toruner M, Harewood GC, Loftus Jr EV, et al. Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:428–34.

    Article  PubMed  Google Scholar 

  84. Picco MF, Pasha S, Leighton JA, et al. Procedure time and the determination of polypoid abnormalities with experience: implementation of a chromoendoscopy program for surveillance colonoscopy for ulcerative colitis. Inflamm Bowel Dis. 2013;19(9):1913–20.

    PubMed  Google Scholar 

  85. SCENIC (Surveillance for Colorectal Endoscopic Neoplasia Detection and Management in Inflammatory Bowel Disease Patients: International Consensus Recommendation); San Francisco 2014. Update on Chromoendoscopy: final recommendations awaiting publication.

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Dr. Farraye is a consultant for Celgene, Cubist, Entera Health, Janssen, and Salix; he has received research support from Cubist and Prometheus outside the submitted work. Dr. Rubin reports grants and personal fees from Salix Pharmaceuticals, grants and personal fees from Shire, grants and personal fees from Warner Chilcott, and personal fees from Actavis outside the submitted work. Dr. Shah reports he is on the Speakers Bureau for Abbvie, Janssen, Santarus (now Salix) and Takeda. He has received grant support from CDC/NIH for Ocean State Crohn’s and Colitis Area Registry (OSCCAR) outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with animal subjects performed by any of the authors. With regard to the authors’ research cited in this paper, all procedures were followed in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000 and 2008.

Author information

Authors and Affiliations

  1. Gastroenterology Associates, Inc., 44 West River Street, Providence, RI, 02904, USA

    Samir A. Shah

  2. Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA

    David T. Rubin

  3. Boston University School of Medicine, Boston, MA, USA

    Francis A. Farraye

Authors
  1. Samir A. Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David T. Rubin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francis A. Farraye
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samir A. Shah.

Additional information

This article is part of the Topical Collection on Large Intestine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shah, S.A., Rubin, D.T. & Farraye, F.A. Chromoendoscopy for Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Disease. Curr Gastroenterol Rep 16, 407 (2014). https://doi.org/10.1007/s11894-014-0407-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11894-014-0407-z

Keywords

Search

Navigation